Attention is focused on whether a treatment for resistant hypertension that cannot be controlled with existing drugs, that is in the final stages of its clinical trial, will succeed in commercialization.

The drug is firibastat, that is developed by Quantum Genomics. Dong Wha Pharmaceuticals owns exclusive commercialization rights to supply the drug in Korea.

The Ministry of Food and Drug Safety approved the multinational Phase III trial for firibastat on the 24th. The clinical trial will verify the efficacy and long-term safety of once-daily oral administration of firibastat for a maximum of 48 weeks in difficult-to-treat resistant hypertension patients.

A total of 750 pa